Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10484627 | Value in Health | 2014 | 9 Pages |
Abstract
Telaprevir plus PR in the Australian setting is cost-effective when compared with PR alone in patients infected with genotype 1 HCV.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Emma BSc, MA (Econ), Alison B Med Sci (Hons), Diploma of Health Economics, Brandon B Med Sci, M Med Sci, MMS,